Show simple item record

Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.

dc.contributor.authorBirzniece, Vita
dc.contributor.authorMeinhardt, Udo J
dc.contributor.authorGibney, James
dc.contributor.authorJohannsson, Gudmundur
dc.contributor.authorArmstrong, Nicola
dc.contributor.authorBaxter, Robert C
dc.contributor.authorHo, Ken K Y
dc.date.accessioned2012-11-29T15:13:24Z
dc.date.available2012-11-29T15:13:24Z
dc.date.issued2012-03
dc.identifier.citationDifferential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women. 2012, 97 (3):1005-12 J. Clin. Endocrinol. Metab.en_GB
dc.identifier.issn1945-7197
dc.identifier.pmid22170716
dc.identifier.doi10.1210/jc.2011-2837
dc.identifier.urihttp://hdl.handle.net/10147/253942
dc.description.abstractGH deficiency causes reduction in muscle and bone mass and an increase in fat mass (FM), the changes reversed by GH replacement. The beneficial effects of GH on fat oxidation and protein anabolism are attenuated more markedly by raloxifene, a selective estrogen receptor modulator, compared with 17β-estradiol. Whether this translates to a long-term detrimental effect on body composition is unknown.
dc.language.isoenen
dc.publisherThe Journal of clinical endocrinology and metabolismen_GB
dc.rightsArchived with thanks to The Journal of clinical endocrinology and metabolismen_GB
dc.subject.meshAdult
dc.subject.meshBody Composition
dc.subject.meshBone Density
dc.subject.meshCross-Over Studies
dc.subject.meshEstradiol
dc.subject.meshFemale
dc.subject.meshHormone Replacement Therapy
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshHypopituitarism
dc.subject.meshMiddle Aged
dc.subject.meshRaloxifene
dc.subject.meshSelective Estrogen Receptor Modulators
dc.subject.meshTreatment Outcome
dc.titleDifferential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.en_GB
dc.typeArticleen
dc.contributor.departmentPituitary Research Unit, Garvan Institute of Medical Research and Department of Endocrinology, St. Vincent's Hospital, and The University of New South Wales, Sydney, New South Wales 2010, Australia.en_GB
dc.identifier.journalThe Journal of clinical endocrinology and metabolismen_GB
dc.description.provinceLeinsteren
html.description.abstractGH deficiency causes reduction in muscle and bone mass and an increase in fat mass (FM), the changes reversed by GH replacement. The beneficial effects of GH on fat oxidation and protein anabolism are attenuated more markedly by raloxifene, a selective estrogen receptor modulator, compared with 17β-estradiol. Whether this translates to a long-term detrimental effect on body composition is unknown.


This item appears in the following Collection(s)

Show simple item record